Editorial
|
|
|
The thalidomide case
|
|
|
Marketing Authorisations
|
|
|
Some improvement in first-line treatment
|
|
|
|
|
|
Better to just suck on hard candy
|
|
|
|
|
|
|
|
Too risky in mildly symptomatic disease
|
|
|
|
|
|
Too risky in mildly symptomatic disease
|
|
|
|
|
|
Marketing authorisation unjustified
|
|
for patients with mildly symptomatic pulmonary arterial hypertension
|
|
|
|
|
|
Too little efficacy, too many risks
|
|
|
|
|
|
|
Continue to use chlorambucil
|
|
|
|
|
|
|
|
Slightly more muscle strength
|
|
|
|
|
|
Adverse Effects
|
|
|
An overall decrease attributable to reduced use of hormone therapy
|
|
|
|
|
|
The most frequent cause is drug therapy for diabetes
|
|
|
|
|
|
|
|
|
|
Necrotising enterocolitis
|
|
|
|
|
|
Gastrointestinal perforation
|
|
|
|
|
|
Abnormal movements and hallucinations
|
|
|
|
Reviews
|
|
|
Many meta-analyses, little benefit
|
|
|
|
|
|
|
A mild disorder; purely symptomatic treatment
|
|
|
|
|
|
|
Relieving symptoms of irritable bowel syndrome
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Non Merci... Charter 2009
|
|
|
|